Cercar

01/01/2022 Retrorenal colon in pediatric patients with urolithiasis: Is the supine position for PCNL advantageous?
Emiliani E., Quiroz Y.Y., Llorens E., Quintian C., Motta G., Villada D., Bujons A.. Retrorenal colon in pediatric patients with urolithiasis: Is the supine position for PCNL advantageous?. Journal of Pediatric Urology. 2022; 18(6)DOI:10.1016/j.jpurol.2022.07.028. PMID:35985922. IF:2.000(Q3/6D).
01/01/2022 Shaping the Undergraduate Curriculum in Europe: Consensus Statement from the European School of Urology
Gómez Rivas J., Somani B., Rodriguez Socarrás M., Marra G., Pearce I., Henningsohn L., Zondervan P., Van Poppel H., N'Dow J., Liatsikos E., Palou J.. Shaping the Undergraduate Curriculum in Europe: Consensus Statement from the European School of Urology. EUROPEAN UROLOGY. 2022; 82(6)DOI:10.1016/j.eururo.2022.09.002. PMID:36163308. IF:23.400(Q1/1D).
01/01/2022 Robotic Radical Prostatectomy for Prostate Cancer in Renal Transplant Recipients: Results from a Multicenter Series
Marra G., Agnello M., Giordano A., Soria F., Oderda M., Dariane C., Timsit M.-O., Branchereau J., Hedli O., Mesnard B., Tilki D., Olsburgh J., Kulkarni M., Kasivisvanathan V., Breda A., Biancone L., Gontero P.. Robotic Radical Prostatectomy for Prostate Cancer in Renal Transplant Recipients: Results from a Multicenter Series. EUROPEAN UROLOGY. 2022; 82(6)DOI:10.1016/j.eururo.2022.05.024. PMID:35750583. IF:23.400(Q1/1D).
01/01/2022 Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non–muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker
Rouprêt M., Gontero P., McCracken S.R.C., Dudderidge T., Stockley J., Kennedy A., Rodriguez O., Sieverink C., Vanié F., Allasia M., Witjes J.A., Colombel M., Longo F., Montanari E., Palou J., Sylvester R.J.. Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non–muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker. European Urology Focus. 2022; 8(6)DOI:10.1016/j.euf.2022.02.006. PMID:35300937. IF:5.400(Q1/2D).
01/01/2022 T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non–muscle-invasive Bladder Cancer Spectrum
Beijert I.J., Hentschel A.E., Bründl J., Compérat E.M., Plass K., Rodríguez O., Subiela Henríquez J.D., Hernández V., de la Peña E., Alemany I., Turturica D., Pisano F., Soria F., Capoun O., Bauerová L., Pešl M., Maxim Bruins H., Runneboom W., Herdegen S., Breyer J., Brisuda A., Calatrava A., Rubio-Briones J., Seles M., Mannweiler S., Bosschieter J., Kusuma V.R.M., Ashabere D., Huebner N., Cotte J., Mertens L.S., Masson-Lecomte A., Liedberg F., Cohen D., Lunelli L., Cussenot O., El Sheikh S., Volanis D., Côté J.-F., Rouprêt M., Haitel A., Shariat S.F., Mostafid A.H., Nieuwenhuijzen J.A., Zigeuner R., Dominguez-Escrig J.L., Hacek J., Zlotta A.R., Burger M., Evert M., Hulsbergen-van de Kaa C.A., van der Heijden A.G., A.L.M. Kiemeney L., Soukup V., Molinaro L., Gontero P., Llorente C., Algaba F., Palou J., N'Dow J., Ribal M.J., van der Kwast T.H., Babjuk M., Sylvester R.J., van Rhijn B.W.G.. T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non–muscle-invasive Bladder Cancer Spectrum. European Urology Focus. 2022; 8(6)DOI:10.1016/j.euf.2022.04.014. PMID:35577750. IF:5.400(Q1/2D).
01/01/2022 Development and Validation of a Novel Skills Training Model for PCNL, an ESUT project
Bozzini G., Maltagliati M., Berti L., Vismara R., Sanguedolce F., Crisci A., Fiore G.B., Redaelli A., Pastore A.L., Gozen A., Breda A., Scoffone C., Ahmed K., Mueller A., Gidaro S., Liatsikos E.. Development and Validation of a Novel Skills Training Model for PCNL, an ESUT project. Acta Biomedica. 2022; 93(4)DOI:10.23750/abm.v93i4.11821. PMID:36043983. IF:(Q/D).